JP2020005603A - 運動能力向上剤 - Google Patents
運動能力向上剤 Download PDFInfo
- Publication number
- JP2020005603A JP2020005603A JP2018131990A JP2018131990A JP2020005603A JP 2020005603 A JP2020005603 A JP 2020005603A JP 2018131990 A JP2018131990 A JP 2018131990A JP 2018131990 A JP2018131990 A JP 2018131990A JP 2020005603 A JP2020005603 A JP 2020005603A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- maintaining
- seq
- action
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000386 athletic effect Effects 0.000 title abstract description 13
- 210000003205 muscle Anatomy 0.000 claims abstract description 38
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 31
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 31
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000009753 muscle formation Effects 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000012423 maintenance Methods 0.000 claims description 17
- 206010028289 Muscle atrophy Diseases 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 230000020763 muscle atrophy Effects 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 102100040669 F-box only protein 32 Human genes 0.000 claims description 5
- 101710191029 F-box only protein 32 Proteins 0.000 claims description 5
- 108010056785 Myogenin Proteins 0.000 claims description 5
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 claims description 4
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 claims description 4
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 claims description 4
- 101000913653 Homo sapiens Fibronectin type III domain-containing protein 5 Proteins 0.000 claims description 4
- 230000037147 athletic performance Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
- 102000004364 Myogenin Human genes 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 230000002269 spontaneous effect Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000006742 locomotor activity Effects 0.000 description 11
- 230000032683 aging Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241001489091 Ganoderma sinense Species 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 4
- 102100032970 Myogenin Human genes 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 208000001076 sarcopenia Diseases 0.000 description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000152045 Themeda triandra Species 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- 241001621841 Alopecurus myosuroides Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100027947 Carnitine O-palmitoyltransferase 1, muscle isoform Human genes 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100030449 Cytochrome c oxidase subunit 7A-related protein, mitochondrial Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000906988 Ganoderma atrum Species 0.000 description 1
- 241001489090 Ganoderma japonicum Species 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000859574 Homo sapiens Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 101000919466 Homo sapiens Cytochrome c oxidase subunit 7A-related protein, mitochondrial Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000760730 Homo sapiens Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 1
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100035077 Myoblast determination protein 1 Human genes 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150006255 TRIM63 gene Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
霊芝(Ganoderma lucidum)の乾燥物20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して霊芝熱水抽出物を1.4g得た。
霊芝(Ganoderma lucidum)の乾燥物100gに900mLのエタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、霊芝エタノール抽出物を1.6g得た。
黒霊芝(Ganoderma sinensis)の乾燥物20gに400mLの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して黒霊芝熱水抽出物を1.1g得た。
黒霊芝(Ganoderma sinensis)の乾燥物100gに900mLのエタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、黒霊芝エタノール抽出物を1.4g得た。
<処方>
成分 含有量(%)
1.霊芝熱水抽出物(製造例1) 30.0
2.米胚芽油 60.0
3.ミツロウ 7.0
4.ビタミンE 3.0
<製造方法>
成分1〜4を混合し、ゼラチン、グリセリン、カラメル色素で構成される被膜に、250mg充填し、乾燥後、軟カプセル剤を得る。
<用法>
1日当り4粒摂取する。
<処方>
成分 含有量(%)
1.霊芝熱水抽出物(製造例1) 20.0
2.コーンスターチ 72.0
3.ショ糖脂肪酸エステル 8.0
<製造方法>
成分1〜3を混合し、2号硬カプセルに250mg充填してカプセル剤を得る。
<用法>
1日当り4粒摂取する。
<処方>
成分 含有量(%)
1.黒霊芝熱水抽出物(製造例3) 1.0
2.クエン酸 6.0
3.ショ糖 10.0
4.香料 1.0
5.水 82.0
<製造方法>
成分1〜4を成分5の一部の水に撹拌溶解する。成分5の残りの水を加えて混合し、殺菌したものを飲料とする。
<用法>
1日当り50mL摂取する。
<処方>
成分 含有量(%)
1.霊芝エタノール抽出物(製造例2) 8.0
2.乳糖 80.0
3.セルロース 12.0
<製造方法>
成分1〜3を乾式法により造粒し、顆粒剤を得る。
<用法>
1日当り1g摂取する。
<処方>
成分 含有量(%)
1.霊芝熱水抽出物(製造例1) 11.0
2.乳糖 60.0
3.還元麦芽糖水飴 25.0
4.ショ糖脂肪酸エステル 4.0
<製造方法>
成分1〜4を混合して打錠成型し、0.5gの錠剤を得る。
<用法>
1日当り2粒摂取する。
<処方>
成分 含有量(%)
1.黒霊芝エタノール抽出物(製造例4) 0.002
2.カラギーナン 2.0
3.ゼラチン 1.0
4.砂糖 28.5
5.精製水 68.498
<製造方法>
成分1〜5を混合し、加熱しながら煮詰め、ゼリーの型に流し込み、冷却する。
<用法>
1日当り1個(100g)を摂取する。
<処方>
成分 含有量(%)
1.霊芝熱水抽出物(製造例1) 15.0
2.乾燥コーンスターチ 65.0
3.微結晶セルロース 20.0
<製造方法>
成分1〜3を混合し、散剤とする。
<用法>
1日当り1包(3g)を摂取する。
3ヶ月齢のHR−1ヘアレスマウスを用い、普通飼料、あるいは霊芝熱水抽出物(製造例1)を2%添加した飼料によって、飼育を18ヶ月間行った。この時点のマウスの月齢は21ヶ月齢である。18ヶ月飼育後、受動型赤外線センサー(スーパーメックスPYS−001、室町機械株式会社製)を用いて、夜間の自発運動量を7日間測定し、7日間の測定値の合計を自発運動量とした。若齢マウスとして3ヶ月齢のHR−1ヘアレスマウスを、同様に、夜間の自発運動量を7日間測定し、7日間の測定値の合計を自発運動量とした。
実験例1の自発運動量測定後、マウスを頚椎脱臼し、右後肢のふくらはぎ筋肉(以下、単に筋肉)を摘出した。遺伝子発現解析は、抽出したRNAからcDNAを調製し、SYBR Greenを用いたリアルタイムPCR法で行った。尚、遺伝子発現解析に使用したプライマーは以下のとおりである。
GATGGCACGCAGCCCTATT(配列番号1)
CGACACGGAGAGTTAAAGGAAGA(配列番号2)
UCP2用のプライマーセット
GCCTCTGGAAAGGGACTTCTC(配列番号3)
ACCAGCTCAGCACAGTTGACA(配列番号4)
UCP3用のプライマーセット
TTTTGCGGACCTCCTCACTT(配列番号5)
TGGATCTGCAGACGGACCTT(配列番号6)
PPARα用のプライマーセット
ACGATGCTGTCCTCCTTGATG(配列番号7)
ACTCGCGTGTGATAAAGCCATT(配列番号8)
GLUT4用のプライマーセット
GATGAGAAACGGAAGTTGGAGAGA(配列番号9)
GCACCACTGCGATGATCAGA(配列番号10)
ADIPOQ受容体1用のプライマーセット
TCCACACAGAGACTGGCAACA(配列番号11)
GCATCGTCAAGATTCCCAGAA(配列番号12)
ACADM用のプライマーセット
AACACTTACTATGCCTCGATTGCA(配列番号13)
CCATAGCCTCCGAAAATCTGAA(配列番号14)
CPT1B用のプライマーセット
GACCCAAAACAGTATCCCAATCA(配列番号15)
CGCCACGGGACCAAAG(配列番号16)
AMPK用のプライマーセット
GTCTGGAGGTGAATTGTTCGACTA(配列番号17)
GCGCGCTTCCACCTCTT(配列番号18)
COX7RP用のプライマーセット
GCTGTGCTTCTGCTCCTGATT(配列番号19)
TGAGCTGGAGAGCAACTTTCC(配列番号20)
CD34用のプライマーセット
CTTCTGCTCCGAGTGCCATT(配列番号21)
ATACCCTGGGCCAACCTCAC(配列番号22)
MYOD1用のプライマーセット
CGAAACACGGGTCATCATAGAA(配列番号23)
TTGGGTAGCCGCTGGTT(配列番号24)
Myogenin用のプライマーセット
GTGGGCATGCAAGGTGTGTA(配列番号25)
TGCGCTTCTCCCTCAGTGT(配列番号26)
FNDC5用のプライマーセット
CAAAGAACAAAGATGAGGTGACCA(配列番号27)
TTCTCCTTGTTGTTATTGGGCT(配列番号28)
IGF−1用のプライマーセット
GTTGCTTCCGGAGCTGTGAT(配列番号29)
GATAGAGCGGGCTGCTTTTG(配列番号30)
IGF−2用のプライマーセット
AACACCGGCTACCACAATG(配列番号31)
GCCAAGCGATAGAGAGAGA(配列番号32)
Atrogin1用のプライマーセット
ATGTTCACAAAGGAAGTACGAAGG(配列番号33)
TGGTCTTCAAGAACTTTCAGTACC(配列番号34)
MuRF1用のプライマーセット
CATCAAGAGCATTGTAGAAGCC(配列番号35)
CTCCTCATCTGTCCCAAAGTC(配列番号36)
MyHC1用のプライマーセット
CCTTGGCACCAATGTCCCGGCTC(配列番号37)
GAAGCGCAATGCAGAGTCGGTG(配列番号38)
MyHC2B用のプライマーセット
GTGATTTCTCCTGTCACCTCTC(配列番号39)
GGAGGACCGCAAGAACGTGCTGA(配列番号40)
IL−1β用のプライマーセット
GATGATAACCTGCTGGTGTGTGA(配列番号41)
GTTGTTCATCTCGGAGCCTGTAG(配列番号42)
IL−6用のプライマーセット
TTCTCTGGGAAATCGTGGAAA(配列番号43)
CTGCAAGTGCATCATCGTTGTT(配列番号44)
CDKN2A用のプライマーセット
TGATGATGATGGGCAACGTT(配列番号45)
TCGAATCTGCACCGTAGTTGAG(配列番号46)
CDKN1A用のプライマーセット
CCGAGAACGGTGGAACTTTG(配列番号47)
AACGCGCTCCCAGACGAA(配列番号48)
TRP53用のプライマーセット
CGACCTATCCTTACCATCATCACA(配列番号49)
GGCACAAACACGAACCTCAA(配列番号50)
SIRT1用のプライマーセット
GCACTAATTCCAAGTTCTATACCC(配列番号51)
GGCAACTCTGATAAATGAACCA(配列番号52)
Claims (9)
- 霊芝を含有することを特徴とする運動能力向上剤。
- 霊芝を含有することを特徴とする筋肉維持剤。
- 筋肉維持作用が、筋形成促進作用である請求項2記載の筋肉維持剤。
- 筋肉維持作用が、筋形成促進に関わる、MyoD1、Myogenin、FNDC5、IGF−1及びIGF−2から選ばれる一種又は二種以上の遺伝子発現促進である、請求項2又は3記載の筋肉維持剤。
- 筋肉維持作用が、筋萎縮抑制作用である請求項2記載の筋肉維持剤。
- 筋肉維持作用が、筋萎縮抑制作用に関わる、Atrogin1及び/又はMuRF1の遺伝子発現抑制である、請求項2又は5記載の筋肉維持剤。
- 筋肉維持作用が、筋形成促進作用及び筋萎縮抑制作用である請求項2記載の筋肉維持剤。
- 請求項1記載の運動能力向上剤を含む運動能力向上用食品組成物。
- 請求項2〜7のいずれか一項記載の筋肉維持剤を含む筋肉維持用食品組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018131990A JP7253764B2 (ja) | 2018-07-12 | 2018-07-12 | 運動能力向上剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018131990A JP7253764B2 (ja) | 2018-07-12 | 2018-07-12 | 運動能力向上剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020005603A true JP2020005603A (ja) | 2020-01-16 |
JP7253764B2 JP7253764B2 (ja) | 2023-04-07 |
Family
ID=69149675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018131990A Active JP7253764B2 (ja) | 2018-07-12 | 2018-07-12 | 運動能力向上剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7253764B2 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05123135A (ja) * | 1991-10-30 | 1993-05-21 | Toyo Seiyaku Kk | 持久力改善飲食品 |
JP2003063981A (ja) * | 2001-08-29 | 2003-03-05 | Nonogawa Shoji Kk | 滋養強壮剤 |
JP2004224700A (ja) * | 2003-01-17 | 2004-08-12 | Nonogawa Shoji Kk | 滋養強壮剤 |
CN101011428A (zh) * | 2007-02-08 | 2007-08-08 | 陈康林 | 一种治疗肌萎缩、肌炎、重症肌无力、肌营养不良的中药 |
JP2009000015A (ja) * | 2007-06-19 | 2009-01-08 | Celeste Inter Cooperation | 食品組成物 |
JP2009062346A (ja) * | 2007-09-10 | 2009-03-26 | Mie Univ | 筋肉増加剤 |
JP2014158441A (ja) * | 2013-02-20 | 2014-09-04 | Nikken Sohonsha Corp | 新規生理活性を有するマンネンタケの栽培方法 |
JP2015199673A (ja) * | 2014-04-04 | 2015-11-12 | 日本メナード化粧品株式会社 | 抗疲労剤 |
KR20170116532A (ko) * | 2016-04-11 | 2017-10-19 | 주식회사 풀무원 | 마카 및 대추야자, 영지버섯, 녹용 발효추출물을 유효성분으로 함유하는 운동수행능력 증진 및 피로회복 증진용 복합조성물 |
JP2018087175A (ja) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | 筋萎縮抑制剤 |
-
2018
- 2018-07-12 JP JP2018131990A patent/JP7253764B2/ja active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05123135A (ja) * | 1991-10-30 | 1993-05-21 | Toyo Seiyaku Kk | 持久力改善飲食品 |
JP2003063981A (ja) * | 2001-08-29 | 2003-03-05 | Nonogawa Shoji Kk | 滋養強壮剤 |
JP2004224700A (ja) * | 2003-01-17 | 2004-08-12 | Nonogawa Shoji Kk | 滋養強壮剤 |
CN101011428A (zh) * | 2007-02-08 | 2007-08-08 | 陈康林 | 一种治疗肌萎缩、肌炎、重症肌无力、肌营养不良的中药 |
JP2009000015A (ja) * | 2007-06-19 | 2009-01-08 | Celeste Inter Cooperation | 食品組成物 |
JP2009062346A (ja) * | 2007-09-10 | 2009-03-26 | Mie Univ | 筋肉増加剤 |
JP2014158441A (ja) * | 2013-02-20 | 2014-09-04 | Nikken Sohonsha Corp | 新規生理活性を有するマンネンタケの栽培方法 |
JP2015199673A (ja) * | 2014-04-04 | 2015-11-12 | 日本メナード化粧品株式会社 | 抗疲労剤 |
KR20170116532A (ko) * | 2016-04-11 | 2017-10-19 | 주식회사 풀무원 | 마카 및 대추야자, 영지버섯, 녹용 발효추출물을 유효성분으로 함유하는 운동수행능력 증진 및 피로회복 증진용 복합조성물 |
JP2018087175A (ja) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | 筋萎縮抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
JP7253764B2 (ja) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009136611A1 (ja) | グルタチオン産生促進剤、グルタチオンの欠乏に起因する疾患の予防・治療剤、飲食品及び飼料 | |
KR20160133811A (ko) | 진세노사이드계 사포닌과 인삼다당체를 함유하는 귀뚜라미의 사육방법과 그 사육방법으로 사육된 귀뚜라미의 추출물 및 그 추출물을 함유하는 식품조성물 | |
KR100887854B1 (ko) | 관절염의 예방제 또는 치료제 | |
US11612629B2 (en) | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient | |
EP3363449B1 (en) | Muscle-enhancing agent | |
US11040080B2 (en) | Feed for domestic animals or supplement for domestic animals, growth-promoting agent for bacterium of genus lactobacillus, and method for promoting growth of bacterium of genus lactobacillus | |
KR102572979B1 (ko) | 갈색거저리 단백질 및 도라지 추출물을 포함하는 근감소증 또는 근위축증 예방 또는 치료용 약학적 조성물 | |
JP7229513B2 (ja) | 脳の機能改善剤および脳の機能改善用飲食品 | |
JP7253764B2 (ja) | 運動能力向上剤 | |
US20150265663A1 (en) | Method for suppressing adipocyte formation | |
JP2006304755A (ja) | ペット用食物 | |
KR20190076979A (ko) | 사료 및 그 제조 방법 | |
KR20210122125A (ko) | 갈색거저리 유충 단백질 또는 이의 가수분해물을 유효성분으로 포함하는 근감소증의 예방, 개선 또는 치료용 조성물 | |
KR102042352B1 (ko) | 땅콩 껍질 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물 | |
JP2010105923A (ja) | アカシア属樹皮由来物を含有するPPARδ発現促進剤 | |
JP6462755B2 (ja) | 脳の機能改善剤および脳の機能改善用飲食品 | |
JP6671367B2 (ja) | 環状ジペプチド含有抗肥満用組成物 | |
EP2101809B1 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
JP6513404B2 (ja) | 脂肪燃焼促進剤及び低体温改善剤 | |
JP6381284B2 (ja) | 記憶障害の予防及び/又は治療のための組成物 | |
KR102669920B1 (ko) | 미역, 포멜로 및 밀배아의 추출물을 포함하는 근육 질환의 예방 또는 개선용 조성물 | |
KR102380291B1 (ko) | 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물 | |
KR102380290B1 (ko) | 아메리카왕거저리 유충 추출물을 포함하는 비만 예방 또는 치료용 조성물 | |
TW201713357A (zh) | 抗肥胖用組成物 | |
KR102121111B1 (ko) | 미국 풍나무 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210514 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230320 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7253764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |